Botanix Pharmaceuticals
Logotype for Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals (BOT) investor relations material

Botanix Pharmaceuticals Q1 2027 TU earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Botanix Pharmaceuticals Limited
Q1 2027 TU earnings summary27 Oct, 2026

Executive summary

  • Sofdra shipments rose 5.3% QoQ to 35,130, while Q1 FY27 net revenue remained $10.1m and operating cash outflow fell 13% to $9.225m.

  • October cost actions target ~50% lower operating expenses for the rest of FY27, with an estimated ~75% of revenue-generating ability retained; this is not a revenue forecast.

  • Priorities include maximizing Sofdra revenue, global licensing and commercialization, complementary in-licensing, revised debt terms and evaluating broader transaction alternatives.

Financial highlights

  • Q1 FY27 Sofdra gross sales rose to $49.3m from $46.7m QoQ, while unaudited net revenue remained $10.1m.

  • Quarter-end cash and cash equivalents were $24.358m, down from $36.631m; inventory was ~$30.8m versus $31.3m in Q4 FY26.

  • Product-sales receipts increased 13% QoQ to $15.161m; net operating cash outflow declined to $9.225m from $10.6m.

  • Operating costs were $11.313m, down 1% QoQ, while manufacturing costs fell 35% to $0.8m from $1.2m.

Outlook and guidance

  • October actions target ~50% lower operating expenses for the remainder of FY27 versus Q1 FY27, with ~60% headcount reduction and estimated retention of ~75% of revenue-generating ability.

  • Remaining FY27 assumptions include ~$2m manufacturing costs, operating and staff costs flat, G&A flat, and gross-to-net payments tracking product sales.

  • Management expects gross-to-net improvement in Q2 FY27 if other factors remain constant; the annual US insurance deductible reset is expected to weigh temporarily on Q3 FY27 GTN.

  • Piramal API technology transfer is expected to reduce cost of goods sold by 25%–40%; completing the process is a priority.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Botanix Pharmaceuticals earnings date

Logotype for Botanix Pharmaceuticals Limited
Q2 202725 Feb, 2027
Botanix Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Botanix Pharmaceuticals earnings date

Logotype for Botanix Pharmaceuticals Limited
Q2 202725 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Botanix Pharmaceuticals Limited is a clinical-stage pharmaceutical company focused on developing treatments for dermatological and antimicrobial conditions. The company's pipeline leverages synthetic cannabidiol (CBD) to address skin diseases such as acne, rosacea, and atopic dermatitis, as well as infections caused by antimicrobial-resistant bacteria. Botanix’s products aim to offer innovative therapies that address unmet medical needs, especially in dermatology, by combining novel formulations with delivery systems that enhance drug efficacy. The company is headquartered in North Perth, Australia, and its shares are listed on the ASX.